Across TCGA pan-cancer cohorts, CRELD2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of CRELD2’s most consistent transcriptional readouts.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where CRELD2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CRELD2 is over-expressed in tumor, although a few such as PDAC and COAD show the opposite, repressed pattern.
PDAC, LUAD, and LSCC are the cancer types where CRELD2 tumor–normal differential expression is most reproducible.
mass-spec protein tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CRELD2 mass-spec protein (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.